Sugi Predict

Sugi Predict / Targets / RRM2

RRM2

Ribonucleoside-diphosphate reductase subunit M2 · P31350 · RRM2 on Sugi Atlas →

1,569 patent compounds predicted against RRM2, 756 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL8683949 SCHEMBL8683949 0.44 10/20
SCHEMBL12453317 SCHEMBL12453317 0.85 9/20
SCHEMBL4382591 SCHEMBL4382591 0.67 9/20
SCHEMBL7749775 SCHEMBL7749775 0.67 9/20
SCHEMBL17835747 SCHEMBL17835747 0.55 9/20
SCHEMBL17835748 SCHEMBL17835748 0.55 9/20
SCHEMBL4380310 SCHEMBL4380310 0.55 9/20
SCHEMBL4390542 SCHEMBL4390542 0.52 9/20
SCHEMBL8683198 SCHEMBL8683198 0.43 9/20
SCHEMBL783292 SCHEMBL783292 0.67 8/20
SCHEMBL783293 SCHEMBL783293 0.67 8/20
SCHEMBL6264236 SCHEMBL6264236 0.55 8/20
SCHEMBL6264240 SCHEMBL6264240 0.55 8/20
SCHEMBL8683286 SCHEMBL8683286 0.48 8/20
SCHEMBL8685397 SCHEMBL8685397 0.45 8/20
SCHEMBL22175351 SCHEMBL22175351 0.39 8/20
SCHEMBL9848709 SCHEMBL9848709 0.54 7/20
SCHEMBL8683080 SCHEMBL8683080 0.50 7/20
SCHEMBL8688249 SCHEMBL8688249 0.49 7/20
SCHEMBL6261110 SCHEMBL6261110 0.71 6/20

Clinical trials — most relevant to RRM2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision PHASE3COMPLETED
S0720: Adjuvant Therapy Based on Gene Expression in Stage IA and IB Non-Small Cell Lung Cancer PHASE2COMPLETED
A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer PHASE2COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia PHASE2COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Investigating the Effect of Vitamin A Supplementation on Retinitis Pigmentosa PHASE1COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia PHASE1RECRUITING
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC nanUNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases nanUNKNOWN
Clinical Manifestations and Biomarkers in Amyotrophic Lateral Sclerosis Type 4 and Other Inherited Neurological Disorders of RNA Processing nanRECRUITING
Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside nanUNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients nanCOMPLETED
Mechanisms of Inherited Retinal Dystrophies Using Whole Genome Sequencing and in Vitro and in Vivo Models nanCOMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma nanCOMPLETED
Molecular Characterisation of Colorectal Cancer Peritoneal Metastases nanRECRUITING
Universal Rare Gene Study: A Registry and Natural History Study of Retinal Dystrophies Associated With Rare Disease-Causing Genetic Variants nanRECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy nanUNKNOWN
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia nanNOT_YET_RECRUITING
Molecular Genetics of Retinal Degenerations nanCOMPLETED
Role of Genetic Factors in the Development of Lung Disease nanRECRUITING
Genetic Factors Affecting the Severity of Beta Thalassemia nanCOMPLETED
Choroid Plexus Dysfunction in Neurological Diseases nanRECRUITING
Study of Specimens From Young Patients With Neuroblastoma nanCOMPLETED
Repeated Bout Effect i Neuromuscular Diseases nanRECRUITING
Investigations Into ISCU Myopathy or Iron Sulfur Scaffold U Protein Myopathy nanCOMPLETED
InsightRP2 Registry nanRECRUITING
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact nanUNKNOWN
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Gene Expression in Patients With Epiretinal Membranes nanUNKNOWN
Prospective Open Clinical and Genetic Study of Patients With Retinitis Pigmentosa nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a RRM2 binder may also engage these)

ProteinNameSimilarity
Q4R7Q7 — 1.000 Q4R7Q7 →
Q4KLN6 — 0.994 Q4KLN6 →
P11157 — 0.989 P11157 →
Q60561 — 0.984 Q60561 →
RRM2B Ribonucleoside-diphosphate reductase subunit 0.977 landscape →
Q5R9G0 — 0.974 Q5R9G0 →
Q6PEE3 — 0.973 Q6PEE3 →
Q4R741 — 0.970 Q4R741 →
P79733 — 0.966 P79733 →
P20651 — 0.932 P20651 →
P48453 — 0.930 P48453 →
P48597 — 0.926 P48597 →
P63328 — 0.926 P63328 →
PPP3CB Serine/threonine protein phosphatase PP2B-alpha catalytic subunit 0.926 landscape →
Q9DFS6 — 0.925 Q9DFS6 →
P48452 — 0.924 P48452 →
Q0IIZ2 — 0.922 Q0IIZ2 →
P63329 — 0.921 P63329 →
A4IHW6 — 0.921 A4IHW6 →
O54984 — 0.920 O54984 →
Q9CZX0 — 0.920 Q9CZX0 →
Q5RIC0 — 0.919 Q5RIC0 →
Q6GNQ1 — 0.919 Q6GNQ1 →
Q2KJ61 — 0.919 Q2KJ61 →
Q9H9T3 — 0.919 Q9H9T3 →
G3V9T7 — 0.918 G3V9T7 →
PPP3CA Protein phosphatase 3 catalytic subunit alpha 0.918 landscape →
GET3 ATPase GET3 0.917 landscape →
GNPDA1 Glucosamine-6-phosphate deaminase 1 0.917 landscape →
A5PJI5 — 0.917 A5PJI5 →